News

A combination of first-line management consisting of validation, explanation, and a positive diagnosis, non-pharmacological treatments, and pharmacological treatment should be considered for pediatric patients with IBS or functional abdominal pain disorders.

The completion of this study concluded the planned clinical development program for nasal nalmefene and the company expects to file a New Drug Application in the second half of 2022.

Future epidemiologic studies may be necessary to investigate further using perinatal data and controlling for other variables.

Investigators suggested that the practice of insurance redlining could be manifesting itself via ACA health exchanges.

Participants with obesity or overweight lost up to 22.5% of their body weight with tirzepatide treatment.

Dr. McKinley-Grant details the new health movement that aims to stop the cycle of suffering for people of color living with psoriatic disease.

In the interest of receiving a variety of opinions from rheumatologists, we asked several key opinion leaders about their thoughts on treating patients with glucocorticoids, regarding their reputation, benefits, risks, and if they are ultimately more helpful or harmful in the treatment of rheumatic diseases.

This episode features a conversation with Dr. Amelle Shillington and Jacob and Ashley Wiley after Shillington diagnosed the extremely rare genetic disease that's afflicted Aislynn Wiley, and only 69 other documented cases worldwide.

Tirzepatide met both coprimary endpoints in SURMOUNT-1, with use contributing to reductions in body weight of up to 22.5% during the 72-week trial and more than 60% of those receiving the 15 mg dose achieving body weight reductions of 20% or more.

“In recent years, the habit of delaying pregnancy because of social and economic reasons has become more common, increasing the possibility of getting pregnant after the onset of the disease," investigators stated. "This fact makes pregnancy a more frequent issue to deal with in the present years.”

In the April 2022 edition of Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives, hosts Drs. Diana Isaacs and Natalie Bellini discuss the implications of the FDA's approval of semaglutide 2.0 mg, the use of novel glycemic control metrics, and a preview of ATTD 2022.

Antibiotic and proton pump inhibitor use was also associated with an increased risk of C difficile infection.

Approximately a quarter of RAPID3 assessments, confirmed with 92% accuracy by DAS28 scores, reported patients had low disease activity and could, therefore, postpone routine clinical visits.

Nancy Holekamp, MD discusses the substantial emotional burden and impact on independence of GA reported in the Geographic Atrophy Insights Survey.

However, comorbidity risk was believed to be substantially different between the two diseases.

The absolute reduction in LFC at week 52 was significantly greater for the pooled tirzepatide 10 mg and 15 mg groups versus the insulin degludec group.

Mental and physical illnesses, such as rheumatoid arthritis, are often driven by social, environmental, and economic factors and may affect disease outcomes.

Dr. Simonetto is involved in several studies using artificial intelligence.

Pediatric patients with CDI had a higher number of previous-day hospital admissions, hospitalizations, and total hospital admissions.

ANCA-associated vasculitis may present like sinusitis, but it typically affects multiple organ systems.

Participants assigned to once-weekly tirzepatide spent significantly more time in tight target range at 52 weeks compared with those assigned to insulin degludec.

71.6% of patients showed a clinically meaningful improvement in total corneal fluorescein staining at 4 weeks after using the ophthalmic solution.

The investigators will now move forward testing the 150 mg dosage of the treatment in a phase 3 trial.

“Understanding the extent of the co-occurrence and identifying factors associated with an increased susceptibility could be relevant to implement case-finding strategies in specific at-risk populations," investigators stated.

The decision to initiate low-dose aspirin use for CVD prevention in adults aged 40 to 59 years with a 10% or greater 10-year CVD risk should be individualized.

Dr. Miriam Vos details the TARGET-NASH study, which indicated a higher prevalence of NAFLD in pediatric patients than previously thought.

Jeffrey Stark, MD, discusses the latest bimekizumab and certolizumab pegol data presented at the 2022 American Academy of Dermatology annual meeting.

New interim data from the RESTORE study indicates that more than 94% of participants preferred the once-nightly dosing of FT218.